RT Journal Article
T1 The onset of ulcerative colitis during treatment with secukinumab: can anti-IL-17A be a trigger for inflammatory bowel disease?
A1 Rodríguez Moncada, Rafael
A1 Vázquez Morón, Juan María
A1 Pallarés Manrique, Héctor
AB In recent months, cases of IBD have been reported in the context of treatment with secukinumab, a monoclonal antibody that blocks IL-17A and which is used in the treatment of certain rheumatic disorders. We present a case of a patient with psoriatic arthritis, with a first-degree relative who had suffered ulcerative colitis, who presented with onset ulcerative colitis in the weeks following treatment initiation with this drug.
SN 1130-0108
YR 2019
FD 2019
LK http://hdl.handle.net/10668/14284
UL http://hdl.handle.net/10668/14284
LA en
DS RISalud
RD Apr 11, 2025